RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
$842.7 Million SDS Poly Acrylamide Gel Electrophoresis Market Forecast, 2030 - Featuring Profiles of 13 Companies Including Abcam, Bio-Rad Laboratories, GE Healthcare, and Thermo Fisher Scientific
There's Reason For Concern Over Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Price
Bio-Rad Laboratories(BIO.US) Officer Sells US$104.02K in Common Stock
$Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael sold 369 shares of common stock on Jun 13, 2024 at an average price of $281.9064 for a total value of $104.02K.Source: Announcement What is state
Is Bio-Rad Laboratories (BIO) a Lucrative Investment?
Form 144 | Bio-Rad Laboratories(BIO.US) Officer Proposes to Sell 104.02K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael intends to sell 369 shares of its common stock on Jun 13, with a total market value of approximately $104.02K.
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Cuts Target Price to $300
Citi analyst Patrick B Donnelly maintains $Bio-Rad Laboratories(BIO.US)$ with a hold rating, and adjusts the target price from $365 to $300.According to TipRanks data, the analyst has a success rate o
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Express News | Jefferies Financial Investment Bank adjusted the rating of Bio-Rad Laboratories (BIO.US) from buy to hold, with a target price of $315.00, down from $440.00.
Jefferies Assumes Bio-Rad Laboratories at Hold, Lowers Price Target of $315
Express News | Bio Rad Laboratories Inc : Jefferies Assumes Coverage With Hold Vs Buy Rating; Price Target $315 Vs $440
Express News | Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target
Bio-Rad Laboratories | 10-Q: Quarterly report
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS